This ESMO Clinical Practice Guidelines provide updated recommendations on management
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …

Melanoma is one of the deadliest skin tumors, accounting for almost 90% of skin cancer
mortality. Although immune therapy and targeted therapy have dramatically changed the …

Patients with cutaneous melanoma can develop in-transit metastases (ITM), most often
localized to limbs. For patients with uveal melanoma that develop metastatic disease, the …

Purpose Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune
checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no …

Simple Summary Melanoma in-transit metastasis has long been effectively treated with
isolated limb perfusion (ILP), a procedure where the limb is treated with high concentrations …

Acral lentiginous melanoma is a rare subtype of melanoma generally associated with poor
outcomes, even when diagnosed at an early stage. The tumor genetic profile remains poorly …

Simple Summary In-transit metastases (ITM) are a challenging aspect of advanced
melanoma, traditionally treated with surgery. However, recent advances in systemic …

Nearly 10% of patients with high-risk early-stage melanoma will develop satellite or in-transit
metastases (ITM), classified as stage III disease similar to lymph node metastases. The …

Melanoma is an aggressive form of skin cancer that, when localized, is highly curable with a
simple surgical excision. However, as it grows in the span of just a few millimeters, its …

Introduction: Melanoma in-transit metastases (ITMs) occur between the primary tumor site
and the regional node field. Most patients with ITMs have a poor prognosis. The treatment of …